CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...